



Avivagen

BANFF CONFERENCE
VIV:TSXV VIVXF:OTCQB
AUGUST 2021



Forward Looking Statement

This presentation includes certain forward-looking statements that are based upon current expectations of management, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking, including those identified by the expressions “anticipate”, “become”, “believe”, “can”, “estimate”, “prospective”, “further”, “targeting”, “would” and similar expressions.

Statements about anticipated market activity in livestock, the potential outcome of current discussions with potential customers and regulators in various jurisdictions; the outcome of regulatory processes currently underway; the implications of trial results to Avivagen’s business; Avivagen’s growth plans for livestock and companion animal products; expectations with respect to the growth of the relationship with UNAHCO, increased orders from UNAHCO and the effects of the UNAHCO relationship on Avivagen’s business in general; Avivagen’s plan to achieve sales goals for its companion animal products; illustrations of the global opportunity for Avivagen; future applications; possible outcomes of milestones and discussions highlighted; future customer wins; path to sales an additional customer adoption of Avivagen’s companion animal products; and Avivagen’s technology extended into human health applications are all forward-looking statements.

These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: the accuracy of third party information included in this presentation; the perceived market opportunity and ongoing discussions with third parties and customers may not translate into orders for Avivagen’s products; Avivagen’s growth strategy may not be as successful as Avivagen anticipates; UNAHCO could stop or fail to increase its orders of Avivagen’s products and Avivagen may not realize the anticipated benefits from the UNAHCO relationship; Avivagen’s ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive, third parties may not perceive Avivagen’s trial as positively as Avivagen does; even if the results are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained for new or existing applications; Avivagen may not be successful with future customer wins or in securing additional customer adoption for its companion animal products; Avivagen may not be successful in expanding its products to additional applications; milestones may not be achieved; unless specifically indicated otherwise, current discussions highlighted with various parties are non-binding and may not lead to binding relationships that have the anticipated results and Avivagen’s technology may not be expanded into or may not receive regulatory approvals for human applications.

Accordingly, you should not place undue reliance on forward-looking statements.

Please refer to the risk factors relating to Avivagen’s business as outlined by the latest Management’s Discussion and Analysis of Financial Condition and Results of Operations and other securities filings available at www.SEDAR.com.

Except as required by law, Avivagen Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

This presentation contains information about the markets in which Avivagen operates which has been obtained from third parties, as indicated throughout. Although Avivagen believes such information to be reasonable, Avivagen has not independently verified such information and does not represent as to its accuracy.

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER TO SELL, AN INVITATION TO INDUCE AN OFFER, OR A SOLICITATION OF AN OFFER TO ACQUIRE THE SHARES OF THE CORPORATION IN ANY JURISDICTION.

AVIVAGEN

LIVING YOUR BEST LIFE!



Investment Summary



Enhancing **Overall Health** by boosting the Immune System while Reducing Inflammation



Attractive Business Model: once the customer adopts, we are fully integrated with a **recurring, increasing revenue profile**



Record sales contract signed in Mexico
New sales in South East Asia
Expanding scientific community acceptance of importance of our product



Companion Animal and Human Markets: **sales on Amazon** via Joint-Venture With Mimi's Rock

Primary Objectives



Dramatic Increase of Overall Sales



Expanding Geographic Reach in All Three Verticals



Deepening and Solidifying the Scientific community's awareness and acceptance



Formation of New Partnerships



What Makes OxC-beta™ Different?

What it is:

- A breakthrough, patent protected health support product

What it does:

- Supports Immune Defenses
while also
- Reducing Inflammation

Why it matters:

- Supports optimal health of all living beings
- Accessible: powder, capsules, chews, etc.
- Affordable: competitive in low cost environments

This could be
like the
discovery of a
new vitamin



Targeting Three Distinct Markets

OxC-beta™

For

Livestock

1.2 Billion Tonne Annual
Worldwide Market

*(Rapid sales growth
phase)*

OxC-beta™

For

Human Health

\$90 Billion U.S. Market

(Launched Feb 1st, 2021)

OxC-beta™

For

Companion Animal

\$635 Million Worldwide
Market


- Each Vertical Represents a Large, Global Market
- Strong patent protection



Livestock Feed Market



Worldwide Purchase Orders of OxC-beta™ to date



- First commercial customer in Philippines, 2017
- Commercial customers followed by Thailand and Taiwan
- Mexico special case: First sale in September 2020, followed by an increase in volume and new customers in 2021.

Proven Efficacy – Again and Again

40+

Clinical and Field trials




- Reduced bacteria
- Reduced somatic cell count
- Increased protein content of milk

- Improved gut health
- Reduced E.coli
- Better maternal, piglet health
- Improved performance

- Reduced C. perfringens
- Improved performance

Strong Competitive Advantages

Supporting Expansion of Approved Markets



1.2B

Tonnes per
year of
feedstock

>50%

“Approved” and
“In Progress”
covers more than
50% of our total
addressable
market

Published Scientific Papers in Highly Respected Scientific Journals



Strategic Growth Plan

Livestock Market

1 Capitalize on current partnerships, with commercial and research field trials on-going

2 Gain regulatory approval in additional countries

3 Add distribution deals in approved markets

Driving
Market
Share and
Revenue
Growth



Recent Developments



Addition of Mr. Lesley Nernberg as a technical sales and marketing consultant, with primary focus on Vietnam, Indonesia and South Korea



MEXICO: 64.5 tonne purchase order, May 2021;
6 tonne purchase order, January 2021; 10 tonne purchase order, September 2020



Expansion of Meyenberg mandate to include Argentina, Costa Rica, Uruguay, Colombia & Peru



NEW ZEALAND: Highly successful dairy trial with NZ Dairy Association;
sales interest growing



CHINA: COFCO BIOTECH assisting VIV with approval in China

- COFCO is a multi-billion dollar company

Competitive Landscape

Probiotics/Prebiotics:

- Mixed efficacy, storage requirements

Essential Oils:

- Old Technology, mixed efficacy, compliance difficulties

Zinc Oxide:

- Environmental issues, banned in many countries

OxC-beta™
Represents a
Next Generation
Antibiotic
Alternative



Human Health Market



Human Wellness, Nutraceutical Opportunity

\$20 Billion On-line U.S. Market

Launched on Amazon U.S. Feb 1st,
2021 under Dr. Tobias Beta Blend
label

Currently in discussions with potential
new partners to expand into international
market



Global Opportunity



Companion Animal Market



OxC-Beta™ for Companion Animal

North America



- Sales on Amazon
- JV with Mimi's Rock (TSXV:MIMI)



Taiwan & Mexico



- First health chews sales in Taiwan in 2019
- First sale to pet food manufacturer in Taiwan in 2020
- First health chews sales in Mexico in 2020



Capitalizing on Current Sales Initiatives

Capital Markets Information

VIV on TSXV
VIVXF on OTCQB

Shares outstanding: 56.8M

Market capitalization: \$19.3M

Recent Price: \$0.34 per share

**As of August 16, 2021*



Upcoming Milestones



Record Sales Contracts and New Country Approvals



Completion of current animal trial studies, with initiation of new ones



Continued research on new applications of OxC-beta and anticipated publications



New Partnerships and full reassessment of those currently established.



APPENDIX

Avivagen

Published Scientific papers

Efficacy of polymers from spontaneous carotenoid oxidation in reducing necrotic enteritis in broilers. **Poultry Science, 2018**

Effects of maternal supplementation with fully oxidised β -carotene on the reproductive performance and immune response of sows, as well as the growth performance of nursing piglets. **British Journal of Nutrition, 2020**

Evaluation of fully oxidized beta-carotene as a feed ingredient to reduce bacterial and somatic cell count in dairy cows with subclinical mastitis. **New Zealand Veterinary Journal 2021**

The β -Carotene-Oxygen Copolymer: its Relationship to Apocarotenoids and β -Carotene Function. **Canadian Journal of Chemistry, 2021**

β -Carotene oxidation products - function and safety, **Food and Chemical Toxicology, 2021**

Effect of oxidized β -carotene-oxygen copolymer compounds on health and performance of pre-and post-weaned pigs. **To Be Submitted**



Avivagen



Investor Presentation • February 2021